Drug-free neurostimulation with multiple shots on goal.

Nexalin is advancing a non-invasive neurostimulation platform for the drug-free treatment of insomnia, anxiety, depression, Alzheimer's disease and dementia, TBI/PTSD and ADHD, built around proprietary Deep Intracranial Frequency Stimulation (DIFS™), with a growing evidence base, next-generation in-clinic and at-home devices, a virtual clinic model, and visible U.S. regulatory catalysts.

Listed Nasdaq: NXL

Platform DIFS™ Neurostimulation

Lead Program HALO™ Clarity

Stage Pivotal + Commercial

Investor Deck

Company Overview 0:30

Nexalin treatment administers a stimulating waveform which is non-invasive, safe and virtually undetectable.

And best of all, without medication.

The Problem

Research suggests anxiety and insomnia may be associated with dysregulation in brain networks and neurochemical pathways.

How It Works

Through our patented, frequency-related, advanced waveform that interacts with the deep centers of the midbrain, our Nexalin device is designed to modulate deep brain networks associated with sleep, mood and cognition.

Non-invasive 40-minute treatment No known or observed side effects

In recent patient surveys, reports indicate a 60%–80% reduction in reported symptoms is most common.

33trials

Clinical trials reported, including 13 international peer-reviewed and 7 validated by neuroimaging

160patients

Planned pivotal HALO™ Clarity insomnia study — triple-blinded, sham-controlled

4markets

Gen-2 approvals highlighted internationally: China, Brazil, Oman and Israel

See Nexalin in action.

A clearer view of the opportunity.

Nexalin combines a differentiated neurostimulation platform, multiple large therapeutic indications, a growing body of clinical and neuroimaging support, and visible regulatory and commercial milestones.

Differentiated DIFS™ technology

Nexalin positions Deep Intracranial Frequency Stimulation as a non-invasive, drug-free approach intended to engage deeper brain structures associated with mood, sleep, cognition and trauma-related conditions.

Higher-output waveform profile

The 15 mA next-generation platform is designed to support deeper-brain targeting than low-power superficial neurostimulation approaches.

Objective validation

Peer-reviewed trials and neuroimaging data support the clinical foundation across multiple indications.

Multiple indications, not a single binary bet

Insomnia, depression, anxiety, Alzheimer's disease and dementia, TBI/PTSD and ADHD create a portfolio-style opportunity with several paths for platform expansion.

Commercial logic that investors can model

The investment case extends beyond hardware, incorporating device revenue, recurring disposable electrodes, service subscriptions and physician-supervised virtual care.

A platform, not one product.

Gen-2 SYNC™, HALO™ Clarity, NeuroCare® and a recurring-revenue model make this broader than a one-device story.

Nexalin extends beyond the clinic. SYNC™ and HALO™ together expand the platform across in-clinic and home-use settings, while NeuroCare® adds remote physician oversight, protocol management and digitally connected treatment across Alzheimer's, mood disorders, TBI and PTSD.

Gen-2 SYNC™ — in-clinic console

The next-generation in-clinic platform targeting deeper brain structures at 15 mA output, with FDA Q-Submission meeting completed for the Alzheimer's disease program.

HALO™ Clarity — at-home headset

A physician-supervised at-home neurostimulation headset designed to extend DIFS™ beyond the clinic, with a planned pivotal insomnia study supporting a De Novo FDA submission.

NeuroCare® — virtual clinic

Remote physician oversight, protocol management and digitally connected treatment across Alzheimer's, mood disorders, TBI and PTSD — an AI-driven virtual clinic designed to expand access.

Why it matters

Device revenue, recurring disposable electrodes, service subscriptions and physician-supervised virtual care together create longer-duration value drivers beyond device placement.

Recent developments and milestones.

Recent company developments include insomnia trial planning, the NeuroCare® launch, expanding neuroimaging validation, the January 2026 ADHD publication and Alzheimer's-focused FDA engagement.

Pivotal HALO™ Clarity insomnia study

Nexalin announced a planned 160-patient, triple-blinded, sham-controlled, decentralized clinical trial with Lindus Health designed to support a planned De Novo FDA submission targeting moderate to severe insomnia.

NeuroCare® virtual clinic launch

The NeuroCare® model adds remote physician oversight, protocol management and digitally connected treatment across Alzheimer's, mood disorders, TBI and PTSD.

ADHD evidence expansion

The January 2026 publication added a peer-reviewed data point showing meaningful attention gains and brain-activity normalization in adults treated with Nexalin-manufactured neurostimulation equipment.

Alzheimer's regulatory engagement

Management has highlighted both Q-Submission acceptance and completion of the FDA Q-Sub meeting for the Gen-2 SYNC™ console in Alzheimer's disease.

HALO™ Clarity extends Nexalin beyond the clinic.

The at-home headset, virtual clinic infrastructure and physician-supervised treatment model support a broader and more scalable care-delivery framework.

Lead Clinical Program

Pivotal HALO™ Clarity insomnia study

A planned 160-patient, triple-blinded, sham-controlled, decentralized clinical trial with Lindus Health, designed to support a planned De Novo FDA submission targeting moderate to severe insomnia.

160 patients

Planned Enrollment

Triple-blinded

Sham-controlled

De Novo

Planned FDA Pathway

Lindus Health

Trial Partner

HALO Clarity at-home neurostimulation headset

Virtual Care Platform

NeuroCare® — AI-driven virtual clinic

NeuroCare® adds remote physician oversight, protocol management and digitally connected treatment across Alzheimer's, mood disorders, TBI and PTSD — designed to expand access across multiple indications.

Remote oversight

Physician Supervision

Multi-indication

Alzheimer's · Mood · TBI/PTSD

Launched

February 2026

Global approvals and international footprint.

Gen-2 approvals have been highlighted in China, Brazil, Oman and Israel, while U.S. programs continue to advance. These international markets underscore the platform's scalability beyond the U.S. regulatory path.

HALO neurostimulation device — global approvals across China, Brazil, Oman and Israel

Technology is the foundation of the platform.

Nexalin's proprietary DIFS™ technology is the core differentiator underpinning the company's platform, enabling non-invasive, drug-free stimulation intended to engage deeper brain structures than conventional low-power superficial neurostimulation approaches.

Proprietary Technology

DIFS™ — Deep Intracranial Frequency Stimulation

DIFS™ is a non-invasive, 15 mA waveform profile designed to engage deeper brain structures associated with mood, sleep, cognition and trauma-related conditions. The platform spans next-generation in-clinic (Gen-2 SYNC™) and at-home (HALO™ Clarity) devices, supported by a virtual clinic model and a growing body of peer-reviewed and neuroimaging-validated evidence.

DIFS waveform engaging deep brain structures via the HALO device

Indication 01

Insomnia

Planned 160-patient pivotal HALO™ Clarity study designed to support a De Novo FDA submission targeting moderate-to-severe insomnia.

Indication 02

Alzheimer's & Dementia

FDA Q-Submission meeting completed for the Gen-2 SYNC™ console in Alzheimer's disease, with ongoing regulatory engagement.

Indication 03

ADHD

January 2026 peer-reviewed publication showed meaningful attention gains and brain-activity normalization in adults treated with Nexalin-manufactured equipment.

Indication 04

TBI/PTSD & Mood

NeuroCare® expands access to remote, physician-supervised treatment across trauma-related and mood-disorder applications.

Mental Health is a Global Epidemic.

The global burden of mental health conditions continues to underscore the need for scalable, drug-free treatment alternatives. Nexalin's platform targets a portfolio of large, underserved indications — creating multiple paths for expansion rather than a single binary bet.

Large brain-health indications

Insomnia, anxiety, depression, Alzheimer's disease and dementia, TBI/PTSD and ADHD create a portfolio-style opportunity with multiple paths for platform expansion.

Drug-free

Non-invasive neurostimulation

A non-invasive, drug-free approach intended to engage deeper brain structures associated with mood, sleep, cognition and trauma-related conditions.

Platform

In-clinic, at-home and virtual care

Gen-2 SYNC™, HALO™ Clarity and NeuroCare® combine to create a care-delivery framework that extends beyond a single device or indication.

A simple narrative.

Non-invasive brain stimulation. Multiple large indications. Widening evidence. Upcoming U.S. catalysts.

Non-invasive brain stimulation

Nexalin's DIFS™ platform is designed as a drug-free, non-invasive approach intended to engage deeper brain structures than conventional low-power neurostimulation.

Multiple large indications

Insomnia, anxiety, depression, Alzheimer's disease and dementia, TBI/PTSD and ADHD create a portfolio-style opportunity with several paths for platform expansion.

Widening evidence base

33 clinical trials reported, including 13 international peer-reviewed studies and 7 studies validated by neuroimaging, with additional publications across mood, adolescent depression and ADHD.

Upcoming U.S. catalysts

The planned HALO™ Clarity pivotal insomnia study and Gen-2 SYNC™ Alzheimer's program represent near-term regulatory milestones that investors can track.